Status:
UNKNOWN
Clinical Evaluation of New Treatment Strategy of Mucous Membrane Pemphigoid Using Large Dose of Prednisolone Plus Intra-lesional of Triamcinolone Acetonide Followed by Combination of Mycophenolate Mofetil, Dapsone and Low Dose Prednisolone
Lead Sponsor:
Tanta University
Conditions:
Benign Mucous Membrane Pemphigoid
Eligibility:
All Genders
40-60 years
Phase:
PHASE2
PHASE3
Brief Summary
Abstract: Mucous membrane pemphigoid (MMP) is an autoimmune blistering disorder characterized by inflammation, blistering, and scarring and predominantly occurring at mucous membranes. Successful trea...
Detailed Description
Before starting any treatment the size of the lesion will be measured and pain score will be evaluated. then patient were treated using large dose of prednisone 60mg daily plus intra-lesional injectio...
Eligibility Criteria
Inclusion
- patients with age references patients confirmed from dermatology department that they had mucous membrane(MMP) pemphigoid- patients are not allergic o to the drugs being used for the treatment
Exclusion
- patients below or above age reference used in the study patients with other oral lesions not being confirmed as MMP patients with systemic diseases preventing using of the drugs
- \-
Key Trial Info
Start Date :
September 30 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 4 2021
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04744623
Start Date
September 30 2020
End Date
November 4 2021
Last Update
February 9 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rehab Fouad Ghouraba
Tanta, Grabia, Egypt, 3111